PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Read more about PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6. Read more about A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6.
Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors. Read more about Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors.
Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core. Read more about Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core.
Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells. Read more about Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells.
Reply to: Binding site for MDL-801 on SIRT6. Read more about Reply to: Binding site for MDL-801 on SIRT6.
Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function. Read more about Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.
Characterization of a natural variant of human NDP52 and its functional consequences on mitophagy. Read more about Characterization of a natural variant of human NDP52 and its functional consequences on mitophagy.
Fragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia. Read more about Fragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia.
Protein arginine methylation: from enigmatic functions to therapeutic targeting. Read more about Protein arginine methylation: from enigmatic functions to therapeutic targeting.